NFKB1 and diabetic cardiomyopathy: On the assumption that NF-κB activated by PKC may function as a core effect in the cardiac hypertrophic response of diabetic cardiomyopathy, as modeled in cultured cardiomyocytes, we used PKCα/β2 inhibitor (Ro-31-8220) and NF-κB inhibitor (BAY11-7082) to study the signal transduction pathway of PKC and its downstream effect on NF-κB.